5-[6-(4-acetyl-3-hydroxy-2-propylphenoxy)hexyl]-tetrazole | 92518-14-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 5-[6-(4-acetyl-3-hydroxy-2-propylphenoxy)hexyl]-tetrazole
• 英文别名: Ethanone, 1-(2-hydroxy-3-propyl-4-((6-(1H-tetrazol-5-yl)hexyl)oxy)phenyl)-；1-[2-hydroxy-3-propyl-4-[6-(2H-tetrazol-5-yl)hexoxy]phenyl]ethanone
• CAS: 92518-14-4
• 化学式: C₁₈H₂₆N₄O₃
• 分子量: 346.429
• InChiKey: WOXRHRBPWQWPSP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  25
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  101
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  7-(4-Acetyl-3-hydroxy-2-propylphenoxy)heptane nitrile 、 叠氮化钠 生成 5-[6-(4-acetyl-3-hydroxy-2-propylphenoxy)hexyl]-tetrazole
  参考文献：
  名称：

  MARSHALL, WINSTON S.;VERGE, JOHN P.

  摘要：

  DOI：

文献信息

• REMEDIES FOR KIDNEY DISEASES AND METHOD FOR SCREENING THE SAME
  申请人：TANABE SEIYAKU CO., LTD.

  公开号：EP1180686A1

  公开（公告）日：2002-02-20

  The present invention provides a method for screening or identifying therapeutic or prophylactic agents for renal diseases, which comprises assaying a test substance for the activity of up-regulating the expression of fatty acid-binding protein (FABP), and novel mouse proximal renal tubular epithelial cell lines useful therein. The present invention also provides therapeutic or prophylactic agents for renal diseases comprising, as an active ingredient, an agent having activity of up-regulating FABP expression; agents for up-regulating the expression of FABP, and for treating or preventing renal diseases, which comprise a compound having activity of peroxisome proliferator-activated receptor (PPAR) agonist or carnitine palmitoyltransferase (CPT) inhibitor or the like.

  本发明提供了一种筛选或鉴定治疗或预防肾脏疾病药物的方法，该方法包括检测试验物质上调脂肪酸结合蛋白（FABP）表达的活性，以及对其有用的新型小鼠近端肾小管上皮细胞系。本发明还提供了治疗或预防肾脏疾病的制剂，其活性成分包括具有上调脂肪酸结合蛋白表达活性的制剂；上调脂肪酸结合蛋白表达和治疗或预防肾脏疾病的制剂，其活性成分包括具有过氧化物酶体增殖激活受体（PPAR）激动剂或肉碱棕榈酰基转移酶（CPT）抑制剂或类似物活性的化合物。
• Therapeutic agents for renal diseases and method for screening the same
  申请人：Tanabe Seiyaku Co., Ltd.

  公开号：US20040185503A1

  公开（公告）日：2004-09-23

  The present invention provides a method for screening or identifying therapeutic or prophylactic agents for renal diseases, which comprises assaying a test substance for the activity of up-regulating the expression of fatty acid-binding protein (FABP), and novel mouse proximal renal tubular epithelial cell lines useful therein. The present invention also provides therapeutic or prophylactic agents for renal diseases comprising, as an active ingredient, an agent having activity of up-regulating FABP expression; agents for up-regulating the expression of FABP, and for treating or preventing renal diseases, which comprise a compound having activity of peroxisome proliferator-activated receptor (PPAR) agonist or carnitine palmitoyltransferase (CPT) inhibitor or the like.

  本发明提供了一种筛选或鉴定治疗或预防肾脏疾病药物的方法，该方法包括检测试验物质上调脂肪酸结合蛋白（FABP）表达的活性，以及对其有用的新型小鼠近端肾小管上皮细胞系。本发明还提供了治疗或预防肾脏疾病的制剂，其活性成分包括具有上调脂肪酸结合蛋白表达活性的制剂；上调脂肪酸结合蛋白表达和治疗或预防肾脏疾病的制剂，其活性成分包括具有过氧化物酶体增殖激活受体（PPAR）激动剂或肉碱棕榈酰基转移酶（CPT）抑制剂或类似物活性的化合物。
• Agents and methods for administration to the central nervous system
  申请人：Crockford David

  公开号：US20060120971A1

  公开（公告）日：2006-06-08

  The present invention provides pharmaceutical compositions and methods for intranasal administration to a subject to increase long-chain acyl CoA levels in the CNS (e.g., the hypothalamus), to reduce food intake and/or reduce appetite, to improve hepatic autoregulation, and/or to treat a metabolic disorder such as diabetes mellitus, metabolic syndrome, hyperglycemia, insulin resistance, glucose intolerance and/or obesity.

  本发明提供了用于对受试者进行鼻内给药的药物组合物和方法，以增加中枢神经系统（如下丘脑）中的长链酰基CoA水平，减少食物摄入和/或降低食欲，改善肝脏自调节，和/或治疗代谢紊乱，如糖尿病、代谢综合征、高血糖、胰岛素抵抗、葡萄糖不耐受和/或肥胖。
• Leukotriene antagonists
  申请人：ELI LILLY AND COMPANY

  公开号：EP0108592B1

  公开（公告）日：1987-09-30
• MARSHALL, WINSTON S.;VERGE, JOHN P.
  作者：MARSHALL, WINSTON S.、VERGE, JOHN P.

  DOI：——

  日期：——